View:
Download DOC
Download PDF
Download XLS
Download XBRL
8-K
0001782223false00017822232022-08-032022-08-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 03, 2022

 

 

Pyxis Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40881

83-1160910

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

150 Cambridgepark Drive

 

Cambridge, Massachusetts

 

02140

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617221-9059

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

PYXS

 

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 3, 2022, Jitendra Wadhane, age 42, was appointed as Chief Accounting Officer and to serve as Principal Accounting Officer of Pyxis Oncology, Inc. (the “Company”). Mr. Wadhane has served as the Company’s Senior Vice President of Finance and Corporate Controller since August 2021. From April 2020 to August 2021, Mr. Wadhane was Head of SEC Reporting and Technical Accounting at Immunovant, Inc., a biopharmaceutical company, and from February 2012 to April 2020, he was a Senior Manager with Ernst & Young LLP, an accounting firm. Mr. Wadhane is a Certified Public Accountant and received his Bachelor’s Degree from the University of Mumbai, and Chartered Accountancy from the Institute of Chartered Accountants of India.

 

Mr. Wadhane has no family relationships with any director or executive officer of the Company. There are no arrangements or understandings between Mr. Wadhane and any other persons pursuant to which he was selected as an officer of the Company, and there are no transactions in which Mr. Wadhane has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Pyxis Oncology, Inc.

 

 

 

 

Date:

August 9, 2022

By:

   /s/ Pamela Connealy

 

 

 

Pamela Connealy
Chief Financial Officer